X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs AUROBINDO PHARMA - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE AUROBINDO PHARMA CADILA HEALTHCARE/
AUROBINDO PHARMA
 
P/E (TTM) x 31.7 14.3 222.0% View Chart
P/BV x 5.9 3.7 160.7% View Chart
Dividend Yield % 0.8 0.4 187.6%  

Financials

 CADILA HEALTHCARE   AUROBINDO PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
AUROBINDO PHARMA
Mar-17
CADILA HEALTHCARE/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs460895 51.4%   
Low Rs305622 49.0%   
Sales per share (Unadj.) Rs92.1254.6 36.2%  
Earnings per share (Unadj.) Rs14.839.3 37.7%  
Cash flow per share (Unadj.) Rs18.546.6 39.7%  
Dividends per share (Unadj.) Rs3.202.50 128.0%  
Dividend yield (eoy) %0.80.3 253.8%  
Book value per share (Unadj.) Rs68.0160.0 42.5%  
Shares outstanding (eoy) m1,023.74585.88 174.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.23.0 139.4%   
Avg P/E ratio x25.819.3 133.7%  
P/CF ratio (eoy) x20.716.3 127.1%  
Price / Book Value ratio x5.64.7 118.7%  
Dividend payout %21.66.4 339.3%   
Avg Mkt Cap Rs m391,581444,390 88.1%   
No. of employees `00016.914.0 120.5%   
Total wages/salary Rs m15,00217,678 84.9%   
Avg. sales/employee Rs Th5,594.510,667.8 52.4%   
Avg. wages/employee Rs Th890.11,264.3 70.4%   
Avg. net profit/employee Rs Th899.91,645.8 54.7%   
INCOME DATA
Net Sales Rs m94,295149,157 63.2%  
Other income Rs m1,2861,159 111.0%   
Total revenues Rs m95,581150,316 63.6%   
Gross profit Rs m19,03634,343 55.4%  
Depreciation Rs m3,7504,276 87.7%   
Interest Rs m450667 67.4%   
Profit before tax Rs m16,12230,558 52.8%   
Minority Interest Rs m33850 673.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-30-   
Tax Rs m1,2897,597 17.0%   
Profit after tax Rs m15,16823,012 65.9%  
Gross profit margin %20.223.0 87.7%  
Effective tax rate %8.024.9 32.2%   
Net profit margin %16.115.4 104.3%  
BALANCE SHEET DATA
Current assets Rs m60,22392,062 65.4%   
Current liabilities Rs m53,05866,223 80.1%   
Net working cap to sales %7.617.3 43.9%  
Current ratio x1.11.4 81.6%  
Inventory Days Days70106 65.9%  
Debtors Days Days8868 130.3%  
Net fixed assets Rs m72,98462,919 116.0%   
Share capital Rs m1,024586 174.8%   
"Free" reserves Rs m68,57693,133 73.6%   
Net worth Rs m69,60093,719 74.3%   
Long term debt Rs m24,6841,814 1,360.7%   
Total assets Rs m152,207162,494 93.7%  
Interest coverage x36.846.8 78.7%   
Debt to equity ratio x0.40 1,832.3%  
Sales to assets ratio x0.60.9 67.5%   
Return on assets %10.314.6 70.4%  
Return on equity %21.824.6 88.8%  
Return on capital %17.932.7 54.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28075,838 28.1%   
Fx outflow Rs m10,87430,224 36.0%   
Net fx Rs m10,40645,613 22.8%   
CASH FLOW
From Operations Rs m13,49532,786 41.2%  
From Investments Rs m-29,103-17,870 162.9%  
From Financial Activity Rs m23,158-19,153 -120.9%  
Net Cashflow Rs m7,556-4,239 -178.3%  

Share Holding

Indian Promoters % 74.8 54.1 138.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 8.0 104.4%  
FIIs % 5.9 27.7 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 10.2 107.8%  
Shareholders   44,069 69,601 63.3%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ELDER PHARMA  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS